Home › Funds › Troluce Capital Advisors LLC › MLYS
Troluce Capital Advisors LLC position in MLYS
MINERALYS THERAPEUTICS INC · Health Care
Troluce Capital Advisors LLC reported holding 50,000 shares of MLYS (MINERALYS THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$1.3M, representing 0.17% of its reported portfolio and ranking #21 among its reported holdings. Troluce Capital Advisors LLC has disclosed MLYS holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Troluce Capital Advisors LLC's MLYS position evolved
Troluce Capital Advisors LLC first disclosed a stake in MLYS in Q1 2026 at 655,000 shares (US$17.7M). Across 2 filings, Troluce Capital Advisors LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 50,000 shares valued at US$1.3M — a reduction of -605,000 shares quarter over quarter.. Notable position changes include a 92% trim in Q2 2026 (shares fell 7% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 655.00K | $17.74M | New |
| Q2 2026 | 50.00K | $1.35M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MLYS and 13F data
MLYS (MINERALYS THERAPEUTICS INC) is a Health Care company. 54 other funds we track also report a position in MLYS — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$207.6M), Catalys Pacific, LLC (US$196.0M), Samsara BioCapital, LLC (US$158.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MLYS
- RA CAPITAL MANAGEMENT, L.P. 7.69M sh · $207.55M · Q2 2026
- Catalys Pacific, LLC 7.80M sh · $196.00M · Q3 2026
- Samsara BioCapital, LLC 5.87M sh · $158.40M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 3.96M sh · $106.79M · Q2 2026
- Laurion Capital Management LP 2.51M sh · $67.62M · Q2 2026
- ORBIMED ADVISORS LLC 2.11M sh · $56.94M · Q2 2026
- SR ONE CAPITAL MANAGEMENT, LP 1.56M sh · $42.20M · Q2 2026
- Andera Partners 1.59M sh · $40.00M · Q3 2026
- SPHERA FUNDS MANAGEMENT LTD. 1.47M sh · $39.66M · Q2 2026
- Ghisallo Capital Management LLC 1.12M sh · $30.35M · Q2 2026
- Logos Global Management LP 1.05M sh · $28.33M · Q2 2026
- ARMISTICE CAPITAL, LLC 1.04M sh · $28.06M · Q2 2026
More on Troluce Capital Advisors LLC
FAQ
How long has Troluce Capital Advisors LLC held MLYS?
Troluce Capital Advisors LLC has disclosed MLYS holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Troluce Capital Advisors LLC's current position in MLYS?
As of Q2 2026, Troluce Capital Advisors LLC holds 50.00K shares of MLYS (MINERALYS THERAPEUTICS INC), valued at $1.35M, representing 0.17% of its reported portfolio and ranking #21.
Has Troluce Capital Advisors LLC been buying or selling MLYS?
In the latest 13F filing (Q2 2026), Troluce Capital Advisors LLC reduced its position in MLYS.
Which other funds hold MLYS?
Other major institutional holders of MLYS include RA CAPITAL MANAGEMENT, L.P., Catalys Pacific, LLC, Samsara BioCapital, LLC, among 54 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.